“The Big Bang Theory” star, who has 18-month-old daughter Matilda with her fiancé Tom Pelphrey, has dealt with her fair share ...

Kaley Cuoco is doing what she feels is best for her daughter, whether you agree with it or not. The 38-year-old “Big Bang ...

Her previous work can be found in OK! Magazine, MyLondon, GRM Daily, and more. Kaley Cuoco/instagram Kaley Cuoco understands why parents hate daylight saving time now. On Monday, Nov. 4 ...

Kaley Cuoco looked stunning as she celebrated her sister Briana's bridal shower at the weekend. The Flight Attendant actress posed for photos in a $395 burgundy mini dress from Simkhai with sheer ...

The latest news and pictures from American actress, Kaley Cuoco. Most famous for her role in TV sitcom, The Big Bang Theory, Kaley has also starred in series such as 8 Simple Rules and Charmed.

The only approved treatments for Alzheimer’s disease are medications with limited effectiveness and a risk of severe, sometimes deadly, side effects. That’s why scientists search for therapies ...

Kaley Cuoco and her husband Tom Pelphrey pulled off an epic Halloween costume this year — and their daughter Matilda was along for the ride. On Thursday, Oct. 31, the Big Bang Theory alum ...

Kaley Cuoco and her fiancé, Tom Pelphrey, won Halloween with their epic costumes — and took inspiration from each other. “ Happy Halloween from Tom, Kaley and their little unicorn!

A drug that is commonly used to treat eye diseases may soon be used to protect against dementia, new research suggests. The drug may also show promise in the treatment of other neurodegenerative ...

As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a different, noninvasive approach to treating Alzheimer’s disease.

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the midstage study has been tied to one death. The interim data ...

driven by ongoing cost-cutting measures and the strong performance of its new Alzheimer’s treatment. The biotech company now expects 2024 adjusted per-share earnings in the range of between $16. ...